| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 04/09/2002 | US6368624 Homogenizing, cooling leaves, freeze drying |
| 04/09/2002 | US6368603 Immunological composition; mixture of antigens |
| 04/09/2002 | US6368602 Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine |
| 04/09/2002 | CA2228595C Novel water-soluble c-ring analogues of 20 (s)-camptothecin |
| 04/09/2002 | CA2184886C Method of strengthening antibacterial action of antibiotics |
| 04/09/2002 | CA2128407C Synthetic peptides for a rubella vaccine |
| 04/09/2002 | CA2095338C Individual stereoisomers of 7-¬3-(aminoalkyl)-1-pyrrolidinyl|-quinolonesand naphthyridones as antibacterial agents |
| 04/09/2002 | CA2093219C Amides of antibiotic ge 2270 factors |
| 04/09/2002 | CA2084790C Endonucleases |
| 04/09/2002 | CA2068349C Rapamycin metabolites |
| 04/06/2002 | CA2358179A1 Anti-inflammatory vectors |
| 04/06/2002 | CA2322564A1 Antiviral compounds |
| 04/04/2002 | WO2002026950A2 Transferases |
| 04/04/2002 | WO2002026943A2 Production of virus-like hcv particles in the cells of insects |
| 04/04/2002 | WO2002026829A1 Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis |
| 04/04/2002 | WO2002026825A2 G-protein coupled receptors |
| 04/04/2002 | WO2002026785A2 Epitopes of virus hepatitis c specifically cd4+ t lymphocytes |
| 04/04/2002 | WO2002026781A2 Ige receptor antagonists |
| 04/04/2002 | WO2002026761A1 Triterpenes having fungicidal activity against yeast |
| 04/04/2002 | WO2002026757A2 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 04/04/2002 | WO2002026753A1 Erythromycin derivatives and medicines containing the same |
| 04/04/2002 | WO2002026744A1 Mpc1001 derivatives |
| 04/04/2002 | WO2002026728A2 Antiviral methods and compounds |
| 04/04/2002 | WO2002026727A2 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai |
| 04/04/2002 | WO2002026726A2 Antiviral compositions and methods of use |
| 04/04/2002 | WO2002026723A1 Compounds useful in the treatment of inflammatory diseases |
| 04/04/2002 | WO2002026722A1 Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| 04/04/2002 | WO2002026717A2 Hydroxy acid integrin antagonists |
| 04/04/2002 | WO2002026716A2 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections |
| 04/04/2002 | WO2002026697A2 Aromatic derivatives with hiv integrase inhibitory properties |
| 04/04/2002 | WO2002026696A1 Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| 04/04/2002 | WO2002026259A1 A pharmaceutical composition for treating acids and its preparation |
| 04/04/2002 | WO2002026257A1 Antibodies to the propeptide of candida albicans and methods of use |
| 04/04/2002 | WO2002026253A1 A vaccine for acids and its preparation and use |
| 04/04/2002 | WO2002026252A1 A vaccine for influenza virus and its preparation |
| 04/04/2002 | WO2002026250A2 Vaccines for proliferative ileitis |
| 04/04/2002 | WO2002026249A2 Methods for inhibition of viral infection |
| 04/04/2002 | WO2002026242A2 Inhibition of systemic infections in humans and vertebrates by dietary fibers |
| 04/04/2002 | WO2002026235A1 Dispersible pharmaceutical cephalosporin compositions, preparation and use thereof |
| 04/04/2002 | WO2002026234A1 Eye drops comprising acyclovir suspension |
| 04/04/2002 | WO2002026227A1 Lactone integrin antagonists |
| 04/04/2002 | WO2002026219A2 Otic microbial combinations for treatment of animals with ruptured tympanic membrane |
| 04/04/2002 | WO2002026214A1 Ion-strength independent sustained release pharmaceutical formulation |
| 04/04/2002 | WO2002026212A2 Microparticle compositions and methods for the manufacture thereof |
| 04/04/2002 | WO2002026211A1 Topical polymeric antimicrobial emulsion |
| 04/04/2002 | WO2002026209A2 Microparticles for delivery of the heterologous nucleic acids |
| 04/04/2002 | WO2002014281A8 Pyridine derivatives as inhibitors of p38 |
| 04/04/2002 | WO2002010339A3 Gene expression profile for kshv infection and methods for treating same |
| 04/04/2002 | WO2002008435A8 Codon-optimized papilloma virus sequences |
| 04/04/2002 | WO2002008195A8 Pyrazolyl biphenyl carboxamides and the use thereof for controlling undesired microorganisms |
| 04/04/2002 | WO2002004407A3 7-substituted tetracycline compounds |
| 04/04/2002 | WO2002003961B1 Microspheres and adjuvants for dna vaccine delivery |
| 04/04/2002 | WO2002000662B1 Improvements in and relating to chromophores |
| 04/04/2002 | WO2002000251A9 Vaccine against foot-and-mouth disease |
| 04/04/2002 | WO2002000167A3 Modified forms of pharmacologically active agents and uses therefor |
| 04/04/2002 | WO2001097795A3 Systems and methods for treating a mucosal surface |
| 04/04/2002 | WO2001088106A3 Novel deoxyribonucleside kinase enzyme multi-substrate variants |
| 04/04/2002 | WO2001085980A3 Enzymatic assays for screening anti-cancer agents |
| 04/04/2002 | WO2001085209A3 Treating t-cell mediated diseases by modulating dr6 activity |
| 04/04/2002 | WO2001078775A3 A method for making an hiv vaccine |
| 04/04/2002 | WO2001077294A3 Hpv-specific short-mers |
| 04/04/2002 | WO2001073034A3 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 04/04/2002 | WO2001073033A3 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 04/04/2002 | WO2001068102A3 Nystatin formulation having reduced toxicity |
| 04/04/2002 | WO2001066566A3 Rotavirus pseudoviral particles and use thereof for vectorizing proteins or nucleic acids |
| 04/04/2002 | WO2001039720A3 Dna polymerase inhibitors, mikanolide and dihydromikanolide |
| 04/04/2002 | WO2001030390A3 Method |
| 04/04/2002 | WO2000070099A3 Differential gene expression in specific regions of the brain in neurodegenerative diseases |
| 04/04/2002 | WO2000057909A9 Attenuated dengue-2 virus vaccine |
| 04/04/2002 | US20020040147 Novel catechols as antimicrobial agents |
| 04/04/2002 | US20020040146 Useful as inhibitors of metalloproteases, e.g. zinc proteases, and which are effective in therapy of disease states associated with vasoconstriction |
| 04/04/2002 | US20020040048 (2S,4R)-4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carboxylic acid N'-isobutyl-N'-(4-methyl-benzenesulfonyl)-hydrazide, for example; inhibitors of metalloproteases, e.g. zinc proteases; vasodilators |
| 04/04/2002 | US20020040022 Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection |
| 04/04/2002 | US20020040009 Novel ratA |
| 04/04/2002 | US20020040007 Novel macrolide antibiotics |
| 04/04/2002 | US20020040002 Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor |
| 04/04/2002 | US20020039998 Administering to human therapeutically effective amount of a combination of drug which is metabolized by cytochrome p450 monooxygenase or pharmaceutically acceptable salt thereof and ritonavir |
| 04/04/2002 | US20020039756 Evaluation and classification of toxicity in humans; obtain samples, incubate with antibodies, detect bound complexes, increased concentration of bound complexes indicates toxicity in humans |
| 04/04/2002 | US20020039736 Reacting aliphatic aminonitrile with water in presence of solid alumina catalyst to form lactam |
| 04/04/2002 | US20020039726 Aids viricides |
| 04/04/2002 | US20020039599 Calibration; administering antiseptic compound |
| 04/04/2002 | US20020039588 Compounds and methods for the treatment and prevention of bacterial infection |
| 04/04/2002 | US20020039585 Mutants of streptococcal toxin c and methods of use |
| 04/04/2002 | US20020039584 Vaccine |
| 04/04/2002 | US20020039583 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 04/04/2002 | US20020039579 Immunoglobulin antibodies |
| 04/04/2002 | US20020039575 Supplying polypepties |
| 04/04/2002 | US20020039574 Delivery of therapeutic gene products by intestinal cell expression |
| 04/04/2002 | US20020039564 Mixture of fatty acid glyceride and hydrocarbon oils |
| 04/04/2002 | US20020039560 Drug delivery |
| 04/04/2002 | DE10045591A1 Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) Site-specific, antibody-mediated activation of proapoptotic cytokines - Amaize (Antibody Mediated Apoptosis Inducing cytokines) |
| 04/04/2002 | DE10044353A1 Unkompetitive Inhibitoren der Helikase-Primase Uncompetitive inhibitors of the helicase-primase |
| 04/04/2002 | CA2426666A1 Ion-strength independent sustained release pharmaceutical formulation |
| 04/04/2002 | CA2425749A1 Otic microbial combinations for treatment of animals with ruptured tympanic membrane |
| 04/04/2002 | CA2424013A1 Triterpenes having fungicidal activity against yeast |
| 04/04/2002 | CA2423919A1 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai |
| 04/04/2002 | CA2423797A1 Antibodies to the propeptide of candida albicans and methods of use |
| 04/04/2002 | CA2423704A1 G-protein coupled receptors |
| 04/04/2002 | CA2423694A1 Transferases |
| 04/04/2002 | CA2423588A1 Improved vaccines for proliferative ileitis and methods of making and using the same |